Treatment for Gastroesophageal disease
A system includes an implantable polymer for increasing the dimensions of layers of tissue. In one embodiment, the implantable polymer is delivered transorally using a scope and injection needle. The system allows for visualization and injection of polymer into the lower esophageal sphincter. Methods of treating gastroesophageal reflux disease include insertion of the distal portion of the injection needle into the esophageal tissue and injection of a polymer liquid to enlarge tissue dimensions. The polymer can be injected at several sites to distribute localized pressures and attain better distribution of the tissue bulking effect.
1. A method of treating a mammalian sphincter in an esophagus of a patient with an injectable liquid polymer implant, to reduce sphincter reflux, said method comprising: providing a catheter and an injector coupled to said catheter, said catheter having a tissue piercing needle distal end; introducing said catheter into said esophagus of the patient; piercing an exterior surface of said sphincter of said esophagus of the patient with said tissue piercing needle distal end on said catheter; advancing said tissue piercing needle distal end a distance in an interior of said sphincter to a tissue site; and controllably delivering said injectable polymer into said tissue site to create a controllable, solid in situ volume-constant implant in said sphincter to bond to and bulk said sphincter and thereby reduce the frequency and quantity of sphincter reflux, wherein said polymer implant comprises a compound of polyisocyanate capped polyol and free polyisocyanate.
2. The method of treating a mammalian sphincter as recited in claim 1 , wherein said catheter is directed to said sphincter transorally.
3. The method of treating a mammalian sphincter as recited in claim 1 , wherein said catheter is directed to said sphincter transorally through an endoscope.
4. The method of treating a mammalian sphincter as recited in claim 1 , wherein the polymer delivery device delivers said volume of polymer to a submucosa of said sphincter.
5. The method of treating a mammalian sphincter as recited in claim 1 , wherein said polymer implant comprises a biocompatible polymer which polymerizes in situ.
6. The method of treating a mammalian sphincter as recited in claim 1 , wherein said polymer implant comprises a biocompatible polymer, which initiates a fibrotic response.
7. The method of treating a mammalian sphincter as recited in claim 1 , wherein said sphincter is an upper esophageal sphincter.
8. The method of treating a mammalian sphincter as recited in claim 1 , wherein said polymer implant comprises a compound of isophorone diisocyanate capped copolymer of polypropylene and polyethylene oxide and free isophorone diisocyanate.
9. The method of treating a mammalian sphincter as recited in claim 1 , wherein said polymer implant comprises a compound of toluene diisocyanate capped copolymer of polypropylene and polyethylene oxide and free toluene diisocyanate.
10. The method of treating a mammalian sphincter as recited in claim 1 , wherein said sphincter is a lower esophageal sphincter.
11. The method of treating a mammalian sphincter as recited in claim 10 , wherein said volume of implant comprises a bolus of a diameter of about 1-10 mm is injected to the lower esophageal sphincter to reduce lower esophageal motion.
12. The method of treating a mammalian sphincter as recited in claim 10 , wherein said volume of implant comprises a bolus of a diameter of about 1-10 mm is implanted in the lower esophageal sphincter to reduce a frequency of a symptom of reflux of stomach contents into an esophagus.
13. The method of treating a mammalian sphincter as recited in claim 10 , wherein said volume of implant comprises a bolus of a diameter of about 1-10 min is injected into the lower esophageal sphincter to reduce an incidence of a sequela of reflux of stomach contents into an esophagus.